 Diphenylhydantoin-induced hypogammaglobulinemia patient human immunodeficiency virus case reversible panhypogammaglobulinemia human immunodeficiency virus HIV patient Onset resolution initiation termination diphenylhydantoin therapy possible seizure rapid alteration peripheral T-cell subpopulations association diphenylhydantoin administration case previous reports diphenylhydantoin-associated hypogammaglobulinemia non-HIV-infected patients addition case regard possible deleterious effects use diphenylhydantoin therapy HIV-associated seizures antiretroviral agent HIV disease